Compare VIVS & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIVS | DCOY |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.2M |
| IPO Year | 2010 | 2014 |
| Metric | VIVS | DCOY |
|---|---|---|
| Price | $0.20 | $1.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 587.7K | ★ 4.1M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,603,000.00 | N/A |
| Revenue This Year | $228,144.28 | N/A |
| Revenue Next Year | N/A | $20.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.82 | N/A |
| 52 Week Low | $0.19 | $0.53 |
| 52 Week High | $3.54 | $13.51 |
| Indicator | VIVS | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 28.24 | 29.82 |
| Support Level | N/A | $0.61 |
| Resistance Level | $0.30 | $3.29 |
| Average True Range (ATR) | 0.02 | 0.69 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 16.30 | 0.33 |
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.